Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.8 USD | -0.73% | -0.37% | +102.99% |
Mar. 28 | Applied Therapeutics Shares Slip 13% After FDA Extends Drug Review | DJ |
Mar. 28 | FDA Extends Review Period for Applied Therapeutics Genetic Disease Treatment | DJ |
Financials (USD)
Sales 2024 * | 10.54M | Sales 2025 * | 68.12M | Capitalization | 725M |
---|---|---|---|---|---|
Net income 2024 * | -70M | Net income 2025 * | -17M | EV / Sales 2024 * | 48.9 x |
Net cash position 2024 * | 210M | Net cash position 2025 * | 170M | EV / Sales 2025 * | 8.15 x |
P/E ratio 2024 * |
-9.71
x | P/E ratio 2025 * |
-20.8
x | Employees | 25 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.09% |
Latest transcript on Applied Therapeutics, Inc.
1 day | -0.73% | ||
1 week | -1.45% | ||
Current month | -4.49% | ||
1 month | +21.86% | ||
3 months | +116.56% | ||
6 months | +157.58% | ||
Current year | +102.99% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 45 | 16-01-19 | |
Les Funtleyder
DFI | Director of Finance/CFO | 55 | 16-05-31 |
Chief Operating Officer | 57 | Dec. 27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jay Skyler
BRD | Director/Board Member | 77 | 19-03-31 |
Joel Marcus
BRD | Director/Board Member | 76 | 16-12-31 |
Teena Lerner
BRD | Director/Board Member | 66 | 17-02-28 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 6.8 | -0.73% | 1,551,492 |
24-03-27 | 6.85 | +2.70% | 676,165 |
24-03-26 | 6.67 | -1.19% | 563,300 |
24-03-25 | 6.75 | 0.00% | 635,484 |
24-03-22 | 6.75 | -1.10% | 1,092,712 |
Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+102.99% | 725M | |
+2.73% | 108B | |
+9.59% | 104B | |
+6.58% | 23.66B | |
-12.59% | 22.1B | |
-3.29% | 19.71B | |
-35.36% | 18.2B | |
-13.29% | 16.19B | |
+4.68% | 13.72B | |
+34.25% | 12.22B |